Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew K P Taggart

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Current Opinion in Cell Biology|June 6, 2003
Telomerase: what are the Est proteins doing?Andrew K P Taggart, Virginia A Zakian
Science (New York, N.Y.)|August 10, 2002
Est1p as a cell cycle-regulated activator of telomere-bound telomeraseAndrew K P Taggart, Shu-Chun Teng, Virginia A Zakian
Nature Structural & Molecular Biology|November 9, 2004
Cell cycle-dependent regulation of yeast telomerase by KuTimothy S Fisher, Andrew K P Taggart, Virginia A Zakian
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109AHong C Shen, Andrew K P Taggart, Larissa C Wilsie, et al.
Biochemical and Biophysical Research Communications|October 28, 2008
Role of GPR81 in lactate-mediated reduction of adipose lipolysisTian-Quan Cai, Ning Ren, Lan Jin, et al.
Journal of Lipid Research|January 13, 2009
Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G)Ning Ren, Rebecca Kaplan, Melba Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2010
The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME propertiesJason E Imbriglio, Daniel DiRocco, Rena Bodner, et al.
Journal of Pharmacological and Toxicological Methods|July 24, 2007
Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonistsEster Carballo-Jane, Lynn S Gerckens, Silvi Luell, et al.
Bioorganic & Medicinal Chemistry Letters|March 16, 2023
Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillationStefan Peukert, Hatice Belgin Gulgeze Efthymiou, Ruowei Mo, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2008
Molecular modeling aided design of nicotinic acid receptor GPR109A agonistsQiaolin Deng, Jessica L Frie, Daria M Marley, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Current Opinion in Cell Biology|June 6, 2003
Telomerase: what are the Est proteins doing?Andrew K P Taggart, Virginia A Zakian
Science (New York, N.Y.)|August 10, 2002
Est1p as a cell cycle-regulated activator of telomere-bound telomeraseAndrew K P Taggart, Shu-Chun Teng, Virginia A Zakian
Nature Structural & Molecular Biology|November 9, 2004
Cell cycle-dependent regulation of yeast telomerase by KuTimothy S Fisher, Andrew K P Taggart, Virginia A Zakian
Bioorganic & Medicinal Chemistry Letters|August 30, 2008
Discovery of pyrazolopyrimidines as the first class of allosteric agonists for the high affinity nicotinic acid receptor GPR109AHong C Shen, Andrew K P Taggart, Larissa C Wilsie, et al.
Biochemical and Biophysical Research Communications|October 28, 2008
Role of GPR81 in lactate-mediated reduction of adipose lipolysisTian-Quan Cai, Ning Ren, Lan Jin, et al.
Journal of Lipid Research|January 13, 2009
Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G)Ning Ren, Rebecca Kaplan, Melba Hernandez, et al.
Bioorganic & Medicinal Chemistry Letters|December 28, 2010
The discovery of high affinity agonists of GPR109a with reduced serum shift and improved ADME propertiesJason E Imbriglio, Daniel DiRocco, Rena Bodner, et al.
Journal of Pharmacological and Toxicological Methods|July 24, 2007
Comparison of rat and dog models of vasodilatation and lipolysis for the calculation of a therapeutic index for GPR109A agonistsEster Carballo-Jane, Lynn S Gerckens, Silvi Luell, et al.
Bioorganic & Medicinal Chemistry Letters|March 16, 2023
Discovery of a brain-sparing GIRK1/4 inhibitor for pharmacological cardioversion of atrial fibrillationStefan Peukert, Hatice Belgin Gulgeze Efthymiou, Ruowei Mo, et al.
Bioorganic & Medicinal Chemistry Letters|September 2, 2008
Molecular modeling aided design of nicotinic acid receptor GPR109A agonistsQiaolin Deng, Jessica L Frie, Daria M Marley, et al.
Pageof 2